Search Results for 'Hiv-Nrti'

Hiv-Nrti published presentations and documents on DocSlides.

DOR + 2 NRTIs vs. DRV + RTV + 2 NRTIs

DOR + 2 NRTIs vs. DRV + RTV + 2 NRTIs

by maximus

DRIVE FORWARD. Doravirine. + 2 NRTIs vs. Darunavi...

Dolutegravir + 2 NRTIs versus Darunavir + RTV + 2 NRTIs

Dolutegravir + 2 NRTIs versus Darunavir + RTV + 2 NRTIs

by roxanne

FLAMINGO. Dolutegravir + 2 NRTIs versus Darunavir ...

Switching the NRTI Backbone to Tenofovir DF-Emtricitabine

Switching the NRTI Backbone to Tenofovir DF-Emtricitabine

by reese

TOTEM. Switching the NRTI Backbone to Tenofovir DF...

LPV-RTV + 3TC vs. LPV-RTV + 2 NRTIs in

LPV-RTV + 3TC vs. LPV-RTV + 2 NRTIs in

by lucy

Virologically. Suppressed. OLE Trial. LPV-RTV + ....

Optimizing HIV treatment

Optimizing HIV treatment

by anderson

Professor Francois Venter. Ezintsha, University of...

HIV Treatment 101 C. Ryan Tomlin, Pharm.D., BCPS, AAHIVP

HIV Treatment 101 C. Ryan Tomlin, Pharm.D., BCPS, AAHIVP

by Powerpixel

Clinical Pharmacist – HIV Medicine. Outline. Wha...

Management of NRTI Resistance

Management of NRTI Resistance

by giovanna-bartolotta

David Spach, MD. Principal . Investigator, NW AET...

Comparison of INSTI vs PI

Comparison of INSTI vs PI

by conchita-marotz

FLAMINGO. GS-236-0103. ACTG . A5257. WAVES. . De...

Comparison of NNRTI vs PI/r

Comparison of NNRTI vs PI/r

by alexa-scheidler

EFV vs LPV/r vs EFV + LPV/r . A5142. Mexican. . ...

HIV/AIDS HIV There are two types of HIV virus HIV 1 and HIV 2 ,most cases are caused by type 1 ,t

HIV/AIDS HIV There are two types of HIV virus HIV 1 and HIV 2 ,most cases are caused by type 1 ,t

by phoebe

HIV1 and slower to progress to AIDS.. Most cases a...

Switch NRTIs to Tenofovir DF-Emtricitabine or Abacavir-Lamivudine

Switch NRTIs to Tenofovir DF-Emtricitabine or Abacavir-Lamivudine

by kylie

STEAL. Switch NRTIs to Tenofovir DF-Emtricitabine ...

A nti- R etroviral T herapy Basics

A nti- R etroviral T herapy Basics

by caroline

E Duke. https://www.hiv.uw.edu/page/treatment/drug...

DTG vs LPV/r (DAWNING): Efficacy

DTG vs LPV/r (DAWNING): Efficacy

by winnie

by Baseline NRTI Resistance . and Second-Line NRTI...

Lopinavir -RTV + NVP +

Lopinavir -RTV + NVP +

by thomas

2 NRTIs in Treatment-Experienced. M97-765 Trial. L...

Switch a ATV/r 3TC Estudio ATLAS-M

Switch a ATV/r 3TC Estudio ATLAS-M

by pamella-moone

ATV/r 300/100 mg QD 3TC 300 mg QD. N = 133. N =...

Superior Efficacy of Dolutegravir (DTG) Plus

Superior Efficacy of Dolutegravir (DTG) Plus

by celsa-spraggs

2 Nucleoside Reverse Transcriptase Inhibitors (NR...

ART Resistance and Second Line Regimens

ART Resistance and Second Line Regimens

by calandra-battersby

Learning Objectives. Understand when to switch to...

CROI 2019: ARV for Prevention and Treatment, HIV Pathogenesis, and Cure

CROI 2019: ARV for Prevention and Treatment, HIV Pathogenesis, and Cure

by brown

Joseph J. Eron, Jr, MD. Professor of Medicine. Uni...

Essentials for Optimal Care of HIV Patients

Essentials for Optimal Care of HIV Patients

by marina-yarberry

Evidence-Based Approaches. Simply Speaking. ®. ...

HIV Pharmacotherapy Focused Update

HIV Pharmacotherapy Focused Update

by yoshiko-marsland

Drew Lambert, . PharmD. lambertd@husson.edu. Huss...

Advances and Challenges in HIV Antiretroviral Therapy

Advances and Challenges in HIV Antiretroviral Therapy

by stefany-barnette

Camille Angle, Meagan Bardan, Hanna Schimjawicz a...

NRTI-sparing SPARTAN PROGRESS

NRTI-sparing SPARTAN PROGRESS

by shepard237

RADAR. NEAT001/ANRS 14. 3 . A4001078. VEMAN. MODER...

Dolutegravir ( Tivicay )

Dolutegravir ( Tivicay )

by brown

Prepared by:. Brian R. Wood, MD. David H. Spach, M...

Switching Antiretroviral Therapy (ART) in Your African American Patients: When and How

Switching Antiretroviral Therapy (ART) in Your African American Patients: When and How

by taylor

Supported by an educational grant from Gilead Scie...

What’s new in the 2019 WHO Guidelines:

What’s new in the 2019 WHO Guidelines:

by elina

Dolutegravir based regimens in first- ad second-li...

ART in Women and Contraception: InSTIs

ART in Women and Contraception: InSTIs

by olivia-moreira

ART in Women and Contraception: InSTIs , Comorbi...

Phase 2 of new ARVs Fostemsavir

Phase 2 of new ARVs Fostemsavir

by conchita-marotz

, . prodrug. of . temsavir. . (attachment inhib...

Ellen G. Chadwick, MD Professor of Pediatrics

Ellen G. Chadwick, MD Professor of Pediatrics

by mitsue-stanley

Northwestern University Feinberg School of Medici...

Opportunities for the use of new ARVs for infants, children and adolescents and updated guidance on

Opportunities for the use of new ARVs for infants, children and adolescents and updated guidance on

by myesha-ticknor

Martina Penazzato MD, PhD. Paediatric lead, HIV D...

Antiretroviral Updates:

Antiretroviral Updates:

by tatyana-admore

New Treatments for HIV. C. Ryan Tomlin, . Pharm.D...

CHILDREN AND HIV Fact sheet Children and HIV July Stopping new HIV infections among children As a result of scaledup HIV prevention services there was a decline in the number of new HIV infections

CHILDREN AND HIV Fact sheet Children and HIV July Stopping new HIV infections among children As a result of scaledup HIV prevention services there was a decline in the number of new HIV infections

by alexa-scheidler

Despite this signi64257cant progress the number o...

Switch PI/R to ETR Etraswitch

Switch PI/R to ETR Etraswitch

by dustin869

Etraswitch. . Study. : Switch PI/r to ETR. Contin...

Dolutegravir vs. Raltegravir

Dolutegravir vs. Raltegravir

by zoe

SPRING-2 Study. Dolutegravir. versus Raltegravir....

Meg Doherty MD MPH PhD 23 July 2018

Meg Doherty MD MPH PhD 23 July 2018

by jordyn

WHO HQ. The role of DTG based regimens in first- a...

Modifying Therapy in the Treatment-experienced Patient:

Modifying Therapy in the Treatment-experienced Patient:

by yoshiko-marsland

When should it be done?. Professor of Medicine. U...

Roy M. Gulick, MD, MPH Gladys and Roland Harriman Professor of Medicine

Roy M. Gulick, MD, MPH Gladys and Roland Harriman Professor of Medicine

by luanne-stotts

Chief, Division of Infectious Diseases. Weill Med...

by liane-varnes

SPARTAN. PROGRESS. RADAR. NEAT001/ANRS 14. 3. A40...

Comparison of NRTI combinations

Comparison of NRTI combinations

by tawny-fly

ZDV/3TC . vs. TDF + FTC. Study 934. ABC/3TC . vs...

Switch to DRV/r

Switch to DRV/r

by mitsue-stanley

monotherapy. MONOI. MONET. PROTEA. DRV600. Design...

HIV Drug Resistance in Well-Resourced Settings

HIV Drug Resistance in Well-Resourced Settings

by faustina-dinatale

Vincent Marconi, . MD. Outline. Transmitted Drug ...